GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mendus AB (publ) IMMU.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

5.88

+9.70%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Mendus AB (publ) — daily IMMU

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Mendus AB (publ) on TradingView ↗
Market value
SEK 306.9m
Last close × shares
Volume
16.3k
Shares, 9 Nov 2026

About Mendus AB (publ)

Its shares trade on Nasdaq Stockholm under the ticker IMMU.ST. It has been listed since 22 April 2013. In the fiscal year to 31 December 2022, it reported revenue of SEK 1.8m and a net loss of SEK 138.8m. At that date it held total assets of SEK 620.4m and shareholders' equity of SEK 514.4m.

Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2013-04-22. The firm develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The firm uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink tumors, prevent relapse, or to kill cancer cells that could not be eliminated with other treatments. The firm has several technology platforms, such as The Combig, Intuvax@, Subcuvax@ and The CD70, among others. The firm has several projects which are related to kidney cancer and liver cancer, among others.

Figures and description from our data supplier, not checked against the company's own report.

More about Mendus AB (publ) →

Latest on Mendus AB (publ)

Our reporting

We have not reported on Mendus AB (publ) yet.

Next results

11 Nov 2026

Due on 11 Nov 2026. Analysts expect earnings of -0.48 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Mendus AB (publ)'s ticker?

Mendus AB (publ) trades as IMMU.ST on Nasdaq Stockholm, under ISIN SE0022239950.

What was Mendus AB (publ)'s last closing price?

5.88 on 9 Nov 2026. The figure is in SEK and is never converted.

When does Mendus AB (publ) next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.